A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

• Status: Withdrawn
• Trial end date: 2022-06-06
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D)

The study will last about 6 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Adults with type 2 diabetes as diagnosed by endocrinologist

• No insulin over past 3 months

• Inadequate glycemic control with A1c ≥8.0% at or within 1 month prior to screening visit

• No history of diabetic ketoacidosis (DKA) or severe hypoglycemia leading to mental status change in the past 6 months

• Willingness and ability to follow the protocol including willingness to commence basal insulin, wear CGM, and communicate with healthcare provider.

Exclusion Criteria:

• Contraindication to use of insulin glargine (e.g., allergy)

• Impaired recognition of hypoglycemia by the participant (as judged by the investigator)